

Thimerosal Content of Routinely Recommended Infant Vaccines Distributed by MDPH (7/99, 7/00, 7/01, 7/04, 5/07)

By 12 months of age

	July 1999			July 2000			July 2001			July 2004			May 2007		
	mcg/0.5ml	doses	total	mcg/0.5ml	doses	total	mcg/0.5ml	doses	total	mcg/0.5ml	doses	total	mcg/0.5ml	doses	total
DTaP ¹	25	3	75	25	3	75	≤0.3	3	≤0.9	≤0.0125	3	≤0.04	≤0.0125	3	≤0.04
Hib ²	25	3	75	0		0	0		0	0		0	0		0
Hep B ³	12.5	3	37.5	0		0	0		0	0		0	0		0
Influenza ⁴										12.5 (0.25ml)	2	25	0	2	0
Total			187.5			75			≤0.9			≤25.04			≤.04
	Percent decrease:			60%			Percent decrease:			>99%			Percent decrease:		
										>87%			Percent decrease:		
										>99%					

By 24 months of age

	July 1999			July 2000			July 2001			July 2004			May 2007		
	mcg/0.5ml	doses	total	mcg/0.5ml	doses	total	mcg/0.5ml	doses	total	mcg/0.5ml	doses	total	mcg/0.5ml	doses	total
DTaP ¹	25	4	100	25	4	100	≤0.3	4	≤1.2	≤0.0125/<0.3	3/1	≤0.34	≤0.0125/<0.3	3/1	≤0.34
Hib ²	25	4	100	0		0	0		0	0		0	0		0
Hep B ³	12.5	3	37.5	0		0	0		0	0		0	0		0
Influenza ⁴										12.5 (0.25ml)	3	37.5	0/≤12.5(0.25ml) ⁵	2/1	≤12.5
Total			237.5			100			≤1.2			≤37.84			≤12.84
	Percent decrease:			58%			Percent decrease:			>99%			Percent decrease:		
										>84%			Percent decrease:		
										>94%					

Chronology of transition to preservative-free pediatric vaccines:

September 1999 - Began distribution of a limited supply of preservative-free hepatitis B vaccine to birthing hospitals for a portion of the birth cohort.

November 1999 - Began distribution of preservative-free hepatitis B vaccine to all birthing hospitals for the entire birth cohort.

February 2000 - Began distribution of preservative-free hepatitis B vaccine to all pediatric providers for all 3 doses of the series.

July 2000 - Began distribution of preservative-free Hib vaccine to all pediatric providers.

March/April 2001 - Began distribution of preservative-free DTaP vaccine to all pediatric providers.

July 2004 - Began distribution of preservative-free DTaP-Hep B-IPV (Pediatrix) combination vaccine, which contains ≤0.0125 mcg/dose.

¹Tripedia was the only DTaP containing product available through MDPH until July 2004 when Pediatrix was introduced. Providers can use either Pediatrix or continue to use Tripedia for the primary series (2, 4, and 6 months). In the table above, for 2004, it was assumed that Pediatrix would be used for the 3 doses in the primary series and one dose of Tripedia would be used at 15-18 months of age. Use of Pediatrix, in place of Tripedia, for all three doses in the primary series reduces the amount of thimerosal due to DTaP immunization to ≤0.04 mcg by 12 months of age and to ≤0.34mcg by 24 months of age. Dependent on which product is used for DTaP vaccination (Tripedia or Pediatrix), the amount of thimerosal from DTaP vaccination can range from ≤0.04mcg to ≤0.9mcg by 12 months of age and from ≤0.34mcg to ≤1.2mcg by 24 months of age. (It is anticipated that Pediatrix will be thimerosal free by the fall of 2007.)

² In April 2002, MDPH began distributing ActHib. Previously, Hibiter was distributed.

³ The hepatitis B formulation is Recombivax.

⁴Since 2004, influenza vaccine has been routinely recommended for all 6-23 month old children. There is currently one influenza vaccine, Fluzone, licensed for use in this age group. There are two formulations of Fluzone, one with thimerosal and one thimerosal free. The thimerosal containing product has 12.5 mcg/0.25ml for children 6-35 months of age. By 24 months of age, children will likely receive 3 doses of influenza vaccine. The amount of thimerosal free influenza vaccine available has increased over the past few years and is expected to continue to increase. As a result, the amount of thimerosal free influenza vaccine purchased by MDPH has increased from 300 hundred doses in 2003 to over 107,000 in 2006. (And, MDPH plans to purchase 125,160 doses in 2007.)

Each flu season, MDPH provides as much preservative free influenza vaccine as is operationally possible. Most of the influenza vaccine available in 2004 contained preservative and for the purposes of the table above, it was assumed that thimerosal containing influenza vaccine was used for all three doses.

⁵By 2007, the amount of thimerosal free influenza vaccine available through MDPH is expected to be sufficient to provide thimerosal free doses to all children in the first year of life and to half the children in the second year of life. Therefore, at least half of the children could receive all thimerosal free vaccine by 24 months of age.